Talon Rescue: Spectrum Gains Marqibo in Bargain Acquisition
In a deal reminiscent of last year's acquisition of struggling Allos Therapeutics Inc., Spectrum Pharmaceuticals Inc. nabbed cash-strapped Talon Therapeutics Inc. for a mere $11.3 million in cash up front, gaining rights to Marqibo, a nanoparticle encapsulation version of microtubule inhibitor vincristine, which gained approval last year in a subset of acute lymphoblastic leukemia (ALL) patients.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter